Compare Herbalife Nutrition Ltd (HLF) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Organon & Co. Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $13.76 (market cap $1.49B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 2.4× Herbalife Nutrition Ltd's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Organon & Co. Common Stock for 0 Days on average.
| HLF | OGN | |
|---|---|---|
Market Cap | $1.49B | $3.62B |
Volume | 1,708,975 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $13.81 |
52-Week Low | $7.75 | $5.70 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $3.32B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $14.19, up 4.26% today, with a bullish technical signal and strong analyst consensus. The stock shows attractive valuation with a P/E of 9.11 and P/S of 0.29, supported by a gross profit margin of 77.7%. Recent news includes a $250 million share repurchase program and a planned CEO transition in October 2026. Cash flow trends indicate improving operational cash generation, with 2026 projected net cash flow turning positive at $50 million.
The outlook for HLF is positive, with a consensus price target of $19.00 implying 34% upside. Risks include negative shareholder equity, high debt levels, and mixed quarterly earnings performance. Revenue stability and margin expansion efforts provide a foundation for growth, but investor caution is warranted due to ongoing leadership changes and competitive pressures in the wellness sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
